secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116327
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata completes enrollment of Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia; topline Q1 2025
--------------------------------------------------------------------------------

- Full enrollment (n=50) achieved for intravenous AP-SA02 in Phase 1b/2a diSArm study targeting Staphylococcus aureus bacteremia.
- Topline data expected in Q1 2025; if positive, may support initiation of a pivotal efficacy trial later in 2025.
- Dose escalated to 5E10 PFU every 6 hours (2E11 PFU/24h) for 5 days without clinically significant adverse events.
- Two blinded subsets observed: one showing evidence of in vivo phage amplification with detectable phage in blood.
- Study supported by $21.6M in funding from Defense Health Agency and Joint Warfighter Medical Research Program via MTEC and NMRC-NAMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/0001104659-24-116327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/tm2428148d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer